Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19)

Blood

Volumn 116, Issue 6, 2010, Pages 962-970

  Hirose, Kinuko ^a   Inukai, Takeshi ^a   Kikuchi, Jiro ^b   Furukawa, Yusuke ^b   Ikawa, Tomokatsu ^c   Kawamoto, Hiroshi ^c   Oram, S Helen ^d   Göttgens, Berthold ^d   Kiyokawa, Nobutaka ^e   Miyagawa, Yoshitaka ^e   Okita, Hajime ^e   Akahane, Koshi ^a   Zhang, Xiaochun ^a   Kuroda, Itaru ^a   Honna, Hiroko ^a   Kagami, Keiko ^a   Goi, Kumiko ^a   Kurosawa, Hidemitsu ^f   Look, A Thomas ^g   Matsui, Hirotaka ^h   Inaba, Toshiya ^h   Sugita, Kanji ^a   more..

^a UNIVERSITY OF YAMANASHI   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c RIKEN Center for Integrative Medical Sciences   (Japan)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956528501     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-09-244673     Document Type: Article

References (45)

1. Rabbitts TH. Chromosomal translocations in human cancer. Nature. 1994;372(6502):143-149.
2. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278(5340):1059-1064. (Pubitemid 27517875)
3. Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci U S A. 1991;88(10):4367-4371. (Pubitemid 21914541)
4. Royer-Pokora B, Loos U, Ludwig WD. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene. 1991;6(10):1887-1893. (Pubitemid 21924023)
5. Wadman I, Li J, Bash RO, et al. Specific in vivo association between the bHLH and LIM proteins implicated in human T cell leukemia. EMBO J. 1994;13(20):4831-4839. (Pubitemid 24319365)
6. Wadman IA, Osada H, Grutz GG, et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J. 1997;16(11):3145-3157. (Pubitemid 27234954)
7. Agulnick AD, Taira M, Breen JJ, Tanaka T, Dawid IB, Westphal H. Interactions of the LIM-domain-binding factor Ldb1 with LIM homeodomain proteins. Nature. 1996;384(6606):270-272. (Pubitemid 26396977)
8. Grütz GG, Bucher K, Lavenir I, Larson T, Larson R, Rabbitts TH. The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells. EMBO J. 1998;17(16):4594-4605. (Pubitemid 28377160)
9. Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell. 1994;78(1):45-57.
10. Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci U S A. 1998;95(7):3890-3895. (Pubitemid 28173224)
11. Yamada Y, Pannell R, Forster A, Rabbitts TH. The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice. Proc Natl Acad Sci U S A. 2000;97(1):320-324. (Pubitemid 30055829)
12. Akashi K, He X, Chen J, Iwasaki H, Niu C, Steenhard B, Zhang J, Haug J, Li L. Transcriptional accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early hematopoiesis. Blood. 2003;101(2):383-389.
13. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511.
14. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350(18):1828-1837.
15. Natkunam Y, Zhao S, Mason DY, et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood. 2007;109(4):1636-1642. (Pubitemid 46239598)
16. McCormack MP, Forster A, Drynan L, Pannell R, Rabbitts TH. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. Mol Cell Biol. 2003;23(24):9003-9013. (Pubitemid 37499791)
17. Fisch P, Boehm T, Lavenir I, et al. T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. Oncogene. 1992;7(12):2389-2397.
18. Larson RC, Fisch P, Larson TA, et al. T cell tumours of disparate phenotype in mice transgenic for Rbtn-2. Oncogene. 1994;9(12):3675-3681. (Pubitemid 24359406)
19. Larson RC, Osada H, Larson TA, Lavenir I, Rabbitts TH. The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene. 1995;11(5):853-862.
20. Neale GA, Rehg JE, Goorha RM. Ectopic expression of rhombotin-2 causes selective expansion of CD4-CD8- lymphocytes in the thymus and T-cell tumors in transgenic mice. Blood. 1995;86(8):3060-3071.
21. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415-419.
22. McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2004;350(9):913-922. (Pubitemid 38252539)
23. Royer-Pokora B, Rogers M, Zhu TH, Schneider S, Loos U, Bolitz U. The TTG-2/RBTN2 T cell oncogene encodes two alternative transcripts from two promoters: the distal promoter is removed by most 11p13 translocations in acute T cell leukaemia's (T-ALL). Oncogene. 1995;10(7):1353-1360.
24. Landry JR, Kinston S, Knezevic K, Donaldson IJ, Green AR, Gottgens B. Fli1, Elf1, and Ets1 regulate the proximal promoter of the LMO2 gene in endothelial cells. Blood. 2005;106(8):2680-2687. (Pubitemid 41510740)
25. Crable SC, Anderson KP. A PAR domain transcription factor is involved in the expression from a hematopoietic-specific promoter for the human LMO2 gene. Blood. 2003;101(12):4757-4764. (Pubitemid 36857732)
26. Inaba T, Roberts WM, Shapiro LH, et al. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science. 1992;257(5069):531-534.
27. Hunger SP, Ohyashiki K, Toyama K, Cleary ML. Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes Dev. 1992;6(9):1608-1620.
28. Mueller CR, Maire P, Schibler U. DBP, a liver-enriched transcriptional activator, is expressed late in ontogeny and its tissue specificity is determined posttranscriptionally. Cell. 1990;61(2):279-291. (Pubitemid 20149359)
29. Drolet D, Scully K, Simmons D, et al. TEF, a transcription factor expressed specifically in the anterior pituitary during embryogenesis, defines a new class of leucine zipper proteins. Genes Dev. 1991;5(10):1739-1753. (Pubitemid 21905871)
30. Yoshihara T, Inaba T, Shapiro LH, Kato JY, Look AT. E2A-HLF-mediated cell transformation requires both the trans-activation domains of E2A and the leucine zipper dimerization domain of HLF. Mol Cell Biol. 1995;15(6):3247-3255.
31. Inukai T, Inaba T, Yoshihara T, Look AT. Cell transformation mediated by homodimeric E2A-HLF transcription factors. Mol Cell Biol. 1997;17(3):1417-1424. (Pubitemid 27097370)
32. Inaba T, Inukai T, Yoshihara T, et al. Reversal of apoptosis by the leukaemia-associated E2A-HLF chimaeric transcription factor. Nature. 1996;382(6591):541-544. (Pubitemid 26260696)
33. Inukai T, Inaba T, Ikushima S, Look AT. The AD1 and AD2 transactivation domains of E2A are essential for the antiapoptotic activity of the chimeric oncoprotein E2A-HLF. Mol Cell Biol. 1998;18(10):6035-6043. (Pubitemid 28450554)
34. Inukai T, Inaba T, Dang J, et al. TEF, an antiapoptotic bZIP transcription factor related to the oncogenic E2A-HLF chimera, inhibits cell growth by down-regulating expression of the common beta chain of cytokine receptors. Blood. 2005;105(11):4437-4444. (Pubitemid 40720792)
35. Smith KS, Rhee JW, Naumovski L, Cleary ML. Disrupted differentiation and oncogenic transformation of lymphoid progenitors in E2A-HLF transgenic mice. Mol Cell Biol. 1999;19(6):4443-4451. (Pubitemid 29242018)
36. Honda H, Inaba T, Suzuki T, et al. Expression of E2A-HLF chimeric protein induced T-cell apoptosis, B-cell maturation arrest, and development of acute lymphoblastic leukemia. Blood. 1999;93(9):2780-2790. (Pubitemid 29200767)
37. Inaba T, Shapiro LH, Funabiki T, et al. DNA-binding specificity and trans-activating potential of the leukemia-associated E2A-hepatic leukemia factor fusion protein. Mol Cell Biol. 1994;14(5):3403-3413. (Pubitemid 24984291)
38. Hunger SP, Brown R, Cleary ML. DNA-binding and transcriptional regulatory properties of hepatic leukemia factor (HLF) and the t(17;19) acute lymphoblastic leukemia chimera E2A-HLF. Mol Cell Biol. 1994;14(9):5986-5996. (Pubitemid 24264427)
39. Inukai T, Zhang X, Goto M, et al. Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity. Leukemia. 2006;20(12):2119-2129. (Pubitemid 44782837)
40. Uno K, Inukai T, Kayagaki N, et al. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood. 2003;101(9):3658-3667. (Pubitemid 36857956)
41. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 2003;33(3):401-406. (Pubitemid 36278858)
42. Kikuchi J, Shimizu R, Wada T, et al. E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1. Stem Cells. 2007;25(10):2439-2447. (Pubitemid 47582736)
43. Garcia IS, Kaneko Y, Gonzalez-Sarmiento R, et al. A study of chromosome 11p13 translocations involving TCR beta and TCR delta in human T cell leukaemia. Oncogene. 1991;6(4):577-582. (Pubitemid 21924121)
44. Van Vlierberghe P, van Grotel M, Beverloo HB, et al. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood. 2006;108(10):3520-3529.
45. Inukai T, Hirose K, Inaba T, Kurosawa H, et al. Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia. 2007;21(2):288-296.